{"id":136389,"date":"2025-10-21T16:25:10","date_gmt":"2025-10-21T16:25:10","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/136389\/"},"modified":"2025-10-21T16:25:10","modified_gmt":"2025-10-21T16:25:10","slug":"ctdna-blood-test-could-change-how-cancer-is-treated","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/136389\/","title":{"rendered":"ctDNA blood test could change how cancer is treated"},"content":{"rendered":"

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.<\/p>\n

BERLIN \u2014 For years, scientists have held out hope<\/a> that tests that look for the molecular fingerprints of a cancer\u2019s presence could help clinicians determine which patients need further treatment after surgery, and which can be considered truly cured after an operation. Perhaps, the thinking goes, those in the latter category could be spared from unnecessary, expensive therapies that can carry serious side effects.<\/p>\n

A study<\/a> presented here Monday bolstered the case that such tests, which detect circulating tumor DNA, or ctDNA, that cancer cells slough off into the blood, could be effective tools.\u00a0<\/p>\n

Researchers used the diagnostics to identify patients who appeared to have remnants of muscle-invasive bladder cancer left after surgery, and directed them to treatment. Those who tested negative were allowed to live treatment-free, and were ultimately found to be at low risk of recurrence.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…\n","protected":false},"author":2,"featured_media":136390,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[7593,110,18,135,19,17,2850],"class_list":{"0":"post-136389","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-biotechnology","9":"tag-cancer","10":"tag-eire","11":"tag-health","12":"tag-ie","13":"tag-ireland","14":"tag-stat"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=136389"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136389\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/136390"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=136389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=136389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=136389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}